Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

NCT06199336 is registered in ClinicalTrials.gov with JHM BioPharma (Tonghua) Co. , Ltd. as lead sponsor.

NCT NCT06199336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06199336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines
Lead sponsor
JHM BioPharma (Tonghua) Co. , Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
January 19, 2024
Completion date
September 9, 2024
Enrollment
190 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe glabellar lines